Back

Smoking cessation medicines and e-cigarettes in smokers with obesity

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Smoking, mental health, and heart disease Stress, Psychosocial and Cultural Aspects of Heart Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Dimitrios Terentes-Printzios

National & Kapodistrian University of Athens, Athens (Greece)

6 More presentations in this session

Presentation thumbnail
The identification, referral and management of patients with cardiac-related distress: a new model to support psychological recovery after a cardiac event
Professor A. Jackson (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Immunoglobulin free light chain-kappa, a novel biomarker of inflammation and cardiovascular risk, decreases after smoking cessation in association with NT-proBNP
Professor K. Hasegawa (Kyoto, JP)
Abstract Slides Video
Presentation thumbnail
Fear of recurrence and its association with mental health outcomes after spontaneous coronary artery dissection (SCAD)
Ms S. Clarke (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Score-2 in heavy smokers: are we underestimating the risk?
Doctor D. Cosmi (Perugia, IT)
Abstract Slides Video
Presentation thumbnail
The Cardiovascular Disease Burden Associated with secondhand smoke, 1990-2019: an age-period-cohort analysis of the Global Burden of Disease study
Doctor H. Jiang (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Smoking, mental health, and heart disease

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Differential effects of heat-not-burn, electronic cigarettes and conventional cigarettes on endothelial glycocalyx.
thumbnail
Congress Presentation
Is the obesity paradox leading to a less stringent secondary prevention strategy in post-acute coronary syndrome patients?
thumbnail
Congress Presentation
Safety and efficacy of dronedarone in overweight and obesity: a post-hoc analysis of the ATHENA trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources